Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EphA2
- Development stage
- Phase 1
- Lead developer
- Biogenea
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
EphA2, or Ephrin type-A receptor 2, is a tumor-associated antigen (TAA) that serves as a target for personalized neoantigenic peptide vaccines. In the context of the TAMAVAQ NeoVaccine, EphA2 peptides are included to stimulate tumor-specific T-cell reactivity, aiming to enhance the immune system's ability to target and eliminate glioma cells that express this antigen.
02
Targets
EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on EphA2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EphA2.